GLP-1 pills and injections have the same side effects
Phase-by-Phase Results Weeks 1-4 (0.25mg): Expected weight loss: 2-5 pounds What youll notice: Possible appetite changes beginning, adjustment to medication Visual change: None apparent Weeks 5-8 (0.5mg): Cumulative weight loss: 6-10 pounds What youll notice: Clearer appetite suppression, reduced portion sizes Visual change: Minimal, possibly clothes fitting slightly better Weeks 9-12 (1.0mg): Cumulative weight loss: 12-18 pounds What youll notice: Consistent weekly losses, significant appetite reduction Visual change: Beginning to be noticeable, especially in face Weeks 13-16 (1.7mg): Cumulative weight loss: 18-25 pounds What youll notice: Strong appetite suppression, eating patterns clearly changed Visual change: Others starting to comment Weeks 17-28 (2.4mg maintenance): Cumulative weight loss: 25-40 pounds What youll notice: Peak weight loss period, maximum medication effect Visual change: Clearly visible transformation Weeks 29-52: Cumulative weight loss: 35-50 pounds What youll notice: Weight loss continuing but gradually slowing Visual change: Dramatic difference from starting point Week 68 (trial endpoint): Cumulative weight loss: 30-50+ pounds (approximately 15% for average responders) What youll notice: Approaching new equilibrium Visual change: Complete transformation for most patients These figures represent typical trajectories
Do not use for single-dose applications requiring preservative-free diluents
Both medications slow gastric emptying and reduce appetite, but their receptor targets create nuanced differences in outcomes
Survodutide (BI 456906) Survodutide is a GLP-1R/GCGR dual agonist from Boehringer Ingelheim, which does not include a GIPR component
So, too, is the battle over who gets to develop and distribute the treatments
